DAB2 mRNA is expressed in normal ovarian epithelial cells but is down-regulated or absent from ovarian carcinoma cell lines. The 770-amino acid predicted protein has an overall 83% identity with the mouse p96 protein, a putative mitogen-responsive phosphoprotein; homology is strongest in the amino-terminal end of the protein in a region corresponding to the phosphotyrosine interaction domain. The down-regulation of DAB2 may play an important role in ovarian carcinogenesis. This gene was initially named DOC2 (for Differentially expressed in Ovarian Cancer) and is distinct from the DOC2A and DOC2B genes (for double C2-like domains, alpha and beta).[3]
↑Albertsen HM, Smith SA, Melis R, Williams B, Holik P, Stevens J, White R (January 1997). "Sequence, genomic structure, and chromosomal assignment of human DOC-2". Genomics. 33 (2): 207–13. doi:10.1006/geno.1996.0185. PMID8660969.
↑Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS (June 1998). "DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer". Oncogene. 16 (18): 2381–7. doi:10.1038/sj.onc.1201769. PMID9620555.
↑ 4.04.1Zhou J, Scholes J, Hsieh JT (February 2003). "Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer". J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID12473651.
↑ 5.05.1He J, Xu J, Xu XX, Hall RA (July 2003). "Cell cycle-dependent phosphorylation of Disabled-2 by cdc2". Oncogene. 22 (29): 4524–30. doi:10.1038/sj.onc.1206767. PMID12881709.
↑Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (April 2002). "The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2". J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID11812785.
↑Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (May 2002). "Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton". Traffic. 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID11967127.
↑Inoue A, Sato O, Homma K, Ikebe M (March 2002). "DOC-2/DAB2 is the binding partner of myosin VI". Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID11906161.
Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS (1994). "Molecular cloning of differentially expressed genes in human epithelial ovarian cancer". Gynecol. Oncol. 52 (2): 247–52. doi:10.1006/gyno.1994.1040. PMID8314147.
Bonaldo MF, Lennon G, Soares MB (1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID8889548.
Xu XX, Yi T, Tang B, Lambeth JD (1998). "Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2". Oncogene. 16 (12): 1561–9. doi:10.1038/sj.onc.1201678. PMID9569023.
Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX (1999). "Disabled-2 inactivation is an early step in ovarian tumorigenicity". Oncogene. 18 (20): 3104–13. doi:10.1038/sj.onc.1202649. PMID10340382.
Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT (1999). "The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer". J. Biol. Chem. 274 (45): 31981–6. doi:10.1074/jbc.274.45.31981. PMID10542228.
Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX (2000). "Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells". Oncogene. 19 (42): 4847–54. doi:10.1038/sj.onc.1203853. PMID11039902.
Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX (2000). "Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2)". Genomics. 70 (3): 381–6. doi:10.1006/geno.2000.6383. PMID11161789.
Morris SM, Cooper JA (2001). "Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2". Traffic. 2 (2): 111–23. doi:10.1034/j.1600-0854.2001.020206.x. PMID11247302.
Zhou J, Hsieh JT (2001). "The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2". J. Biol. Chem. 276 (30): 27793–8. doi:10.1074/jbc.M102803200. PMID11371563.
Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (2002). "The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2". J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID11812785.
Inoue A, Sato O, Homma K, Ikebe M (2002). "DOC-2/DAB2 is the binding partner of myosin VI". Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID11906161.
Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (2002). "Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton". Traffic. 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID11967127.
Zhou J, Scholes J, Hsieh JT (2003). "Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer". J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID12473651.